The Role of Dexmedetomidine in Paroxysmal Sympathetic Hyperactivity: A Systematic Review
Annals of Pharmacotherapy · 2024-06 · 58 (6) · 614-621
DOI: 10.1177/10600280231194708 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 22.08.2023. Verfasst von Cole R Jerousek und 1 weiteren Autor:innen. Beteiligte Einrichtung: The University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA. Hauptthemen laut MEDLINE: Dexmedetomidine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
The objective was to evaluate the efficacy and safety of dexmedetomidine in the treatment and prophylaxis of paroxysmal sympathetic hyperactivity (PSH). Data Sources: A review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and queried Embase, MEDLINE (PubMed), Cochrane CENTRAL, Web of Science, SciELO, Korean Journal Index (Clarivate), Global Index Medicus, and CINAHL Plus for results through June 2023. Study Selection and Data Extraction: Studies providing efficacy or safety data associated with dexmedetomidine with a reported diagnosis of PSH were included. Exclusion of studies in pediatric populations, without quantitative and qualitative outcome data, and not readily translatable to English was adhered to. Data Synthesis: Thirteen observational studies of 178 patients were included in the qualitative analysis. Reductions in PSH frequency or symptom severity were reported in 44 of 48 patients who received dexmedetomidine for acute treatment. Prophylactic use of dexmedetomidine was associated with reductions in PSH-Assessment Measure (PSH-AM) scores in postsurgical patients with traumatic brain injuries (TBIs). Adverse events associated with dexmedetomidine were either absent or reported as none. Relevance to Patient Care and Clinical Practice: This review supports the safe and effective use of dexmedetomidine in the treatment and prophylaxis of PSH. Further investigation is required to determine optimal dosing strategies and the extent to which PSH etiology correlated to the efficacy of dexmedetomidine.
Conclusions
The use of dexmedetomidine appears to be both efficacious and safe for the treatment and prevention of PSH in patients experiencing a TBI. Additional research is needed to elucidate dosing strategies, titration parameters, and duration of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.
ORCID-Profile: Cole R Jerousek, Justin P Reinert
Zitieren
APA
Jerousek, C. R., & Reinert, J. P. (2024). The Role of Dexmedetomidine in Paroxysmal Sympathetic Hyperactivity: A Systematic Review. Annals of Pharmacotherapy, 58(6), 614-621. https://doi.org/10.1177/10600280231194708
Vancouver
Jerousek CR, Reinert JP. The Role of Dexmedetomidine in Paroxysmal Sympathetic Hyperactivity: A Systematic Review. Annals of Pharmacotherapy. 2024;58(6):614-621. doi:10.1177/10600280231194708
BibTeX
@article{Jerousek2024,
author = {Jerousek, Cole R and Reinert, Justin P},
title = {The Role of Dexmedetomidine in Paroxysmal Sympathetic Hyperactivity: A Systematic Review},
journal = {Annals of Pharmacotherapy},
year = {2024},
volume = {58},
number = {6},
pages = {614--621},
doi = {10.1177/10600280231194708}
}
EUVIMED